1. Home
  2. CFFN vs NUVB Comparison

CFFN vs NUVB Comparison

Compare CFFN & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CFFN
  • NUVB
  • Stock Information
  • Founded
  • CFFN 1893
  • NUVB 2018
  • Country
  • CFFN United States
  • NUVB United States
  • Employees
  • CFFN N/A
  • NUVB N/A
  • Industry
  • CFFN Savings Institutions
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CFFN Finance
  • NUVB Health Care
  • Exchange
  • CFFN Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • CFFN 734.6M
  • NUVB 831.3M
  • IPO Year
  • CFFN 1999
  • NUVB N/A
  • Fundamental
  • Price
  • CFFN $6.01
  • NUVB $2.37
  • Analyst Decision
  • CFFN Hold
  • NUVB Strong Buy
  • Analyst Count
  • CFFN 2
  • NUVB 6
  • Target Price
  • CFFN $6.50
  • NUVB $7.67
  • AVG Volume (30 Days)
  • CFFN 758.6K
  • NUVB 2.9M
  • Earning Date
  • CFFN 01-29-2025
  • NUVB 02-27-2025
  • Dividend Yield
  • CFFN 5.59%
  • NUVB N/A
  • EPS Growth
  • CFFN N/A
  • NUVB N/A
  • EPS
  • CFFN 0.39
  • NUVB N/A
  • Revenue
  • CFFN $181,716,000.00
  • NUVB $2,162,000.00
  • Revenue This Year
  • CFFN N/A
  • NUVB N/A
  • Revenue Next Year
  • CFFN $9.27
  • NUVB $663.04
  • P/E Ratio
  • CFFN $15.57
  • NUVB N/A
  • Revenue Growth
  • CFFN N/A
  • NUVB N/A
  • 52 Week Low
  • CFFN $4.76
  • NUVB $1.53
  • 52 Week High
  • CFFN $7.20
  • NUVB $4.16
  • Technical
  • Relative Strength Index (RSI)
  • CFFN 53.32
  • NUVB 43.45
  • Support Level
  • CFFN $5.59
  • NUVB $2.23
  • Resistance Level
  • CFFN $6.06
  • NUVB $2.54
  • Average True Range (ATR)
  • CFFN 0.17
  • NUVB 0.18
  • MACD
  • CFFN 0.06
  • NUVB -0.03
  • Stochastic Oscillator
  • CFFN 76.47
  • NUVB 31.93

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank, Capitol Federal Savings Bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It primarily serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: